A Business Leader out to slash Profiteering in Medicine Trade

New Delhi: It is really strange that a business leader should holler for slashing of profit in trade but, that is what is making his voice credible and compelling the powers that be to listen to Purushottam Somani’s prescription – put 30 % trade margin on entire medicines to protect both patients and government’s earning from income tax and GST. It may not seem possible but he is brimming with confidence chanting Modiji Hai to Mumkin Hai.

30% cap on cancer medicines due to his efforts has proved a booster dose for Mr Somani, Founder President of Nizamabad Commerce & Industry. This has toughened his resolve to take his fight to logical end- to get abnormal MRP, sometimes up to 5,000%, slashed to 30% across all medicines. Exposing threadbare the scams of high MRP in medicine business, Mr Somani in a press conference in Press club of India on 17 September, demanded to end category of drugs into schedule and non schedule category and put 30% margin cap on entire medicines.

Mr Somani said Govt. is losing approximately 3.3 lacs crore income tax and 1.1 lacs crore GST  from hospitals doctors and attached medical shops as manufactures are printing abnormal MRP upto 5000 % to get the business.

According to him, there is no need of bifurcation of schedule or non-schedule drugs. Govt. can put 30% trade margin cap on entire medicines, lifesaving drugs, devices on MRP prices on or above Rs. 2/- MRP (for viability) like cancer drugs. He said, ‘Entire drugs and devices prices will be slashed upto 90% without affecting manufacture’s selling price and reasonable profit to wholesalers and retailers but 130 crore people will be benefited and getting out of financial crunch because medical expenses are far more than food expenses.

Mr Somani further said, ‘ I have given representation to Hon’ble Shri Narendra Modiji on 20/10/2018 for trade margin cap on medicine & from 08/03/2019, Govt. has brought trade margin cap on 390 cancer drugs without affecting the manufacturers selling prices & reasonable profit to wholesalers & retailers without losing any revenue by Just putting 30% trade margin cap on MRP on manufacture’s selling prices. Due to this, up to 87% cancer drug prices has been slashed and 26 lacs cancer patients are getting affordable medicines & saving their lives.

According to him, there are 83% non-schedule drugs & 17% schedule drugs. Non schedule drugs prices MRP is printed upto 5000% more on retailers purchase cost and schedule drugs. Manufactures are not earning any profit, contrary they are losing due to DPCO therefore they avoid manufacturing medicine under DPCO. Before GST, excise duty was on 65% on MRP prices of medicines. Now GST is on selling prices, not on MRP and there is no drug control policy on ceiling the prices. Therefore on demand of hospital owners, Doctors and attached medical shops manufactures are printing abnormal MRP upto 5000% to get the business.

Mr.Somani said, ‘I have studied for 1107 medicines of 5 leading companies of which average MRP is 500% more than retailer’s purchasing cost. As on today, manufacture’s total turnover is 3 lac crore (without exports) whichmeans retailers turnover should be 15 lac crore. So, the question is whether govt is getting income tax and GST on 15 crores ? The answer is–no. Govt. is getting income tax and GST on only approximately 4 lac crore only which means Govt. is losing approximately 3.3 lacs crore in income tax and 1.1 lacs crore in GST, but public is getting looted by buying medicines on MRP. By trade margin cap govt. will not lose revenue and public will be safeguarded.

P.R Somani added,  ‘One the on hand the govt. is saying to buy generic medicines but on other hand generic medicine’s MRP is printed similar to branded medicines. As such there is no difference or one cannot differentiate in generic & branded medicines as both are printed with the brand name. This must be kept in mind, after expiry of patent all are generic medicines only. There is no difference in quality.

Summing up, Mr Somani Said, ‘ by putting trade margin caps, all the medicines prices will be approximate near to Pradhan Mantri Bhartiya Janaushadhi. This will also lead to coming down of claims related to Ayushman Yojana, Health Insurance premium and insurance by 50 to 80 % .

Related Posts

  • Pharma
  • April 19, 2024
  • 22 views
US FDA Mandates Label Updates On CAR-T Cancer Therapies

Washington: The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called “boxed warning” to highlight the serious risk of T-cell blood…

  • Pharma
  • April 19, 2024
  • 15 views
Karnataka Fails To Take Action Against 1,700 Fake Doctors

Bengaluru: A startling revelation has come to light nearly 17,00 fake doctors have been identified in the AYUSH department in Karnataka. Shockingly, despite these discoveries, no significant action has been taken…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Mandates Label Updates On CAR-T Cancer Therapies

US FDA Mandates Label Updates On CAR-T Cancer Therapies

Karnataka Fails To Take Action Against 1,700 Fake Doctors

Karnataka Fails To Take Action Against 1,700 Fake Doctors

Chhattisgarh Pharmacy Council Issued Certificates For Hundreds Of Fake Pharmacists Without Verification

Chhattisgarh Pharmacy Council Issued Certificates For Hundreds Of Fake Pharmacists Without Verification

Gujarat FDCA Approved 133 New Drug Manufacturing Units In FY24

Gujarat FDCA Approved 133 New Drug Manufacturing Units In FY24

DCGI Informs SLAs Antibiotic Combo Meropenem 1 Mg & EDTA For Injection Has No Approval

DCGI Informs SLAs Antibiotic Combo Meropenem 1 Mg & EDTA For Injection Has No Approval

DCA Raids Two Illegal Pharmacies; Seizes Stocks Of Over 60 Types Of Drugs

DCA Raids Two Illegal Pharmacies; Seizes Stocks Of Over 60 Types Of Drugs